2025
Current Advances in PARP1‐Targeted Theranostics
Tong J, Chen B, Volpi T, Li Y, Ellison P, Cai Z. Current Advances in PARP1‐Targeted Theranostics. Journal Of Labelled Compounds And Radiopharmaceuticals 2025, 68: e4135. PMID: 39995212, DOI: 10.1002/jlcr.4135.Peer-Reviewed Original ResearchConceptsPoly (ADP-ribose) polymerase 1Blood-brain barrierCentral nervous systemBlood-tumor barrierPotential clinical useBRCA mutationsHomologous recombination repair pathwayPARP inhibitorsPharmacodynamic evaluationPatient stratificationPersonalized oncologyPharmacological characteristicsClinical useBrain tumorsBrain barrierDiagnostic imagingPET imagingCancerNervous systemTherapeutic interventionsBrain cancerPathophysiological conditionsTreatment assessmentPARPiNeurological disorders
2024
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Huseman E, Lo A, Fedorova O, Elia J, Gueble S, Lin K, Sundaram R, Oh J, Liu J, Menges F, Rees M, Ronan M, Roth J, Batista V, Crawford J, Pyle A, Bindra R, Herzon S. Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers. Journal Of The American Chemical Society 2024, 146: 18241-18252. PMID: 38815248, PMCID: PMC11409917, DOI: 10.1021/jacs.3c06483.Peer-Reviewed Original ResearchDNA repair capacityDifferential DNA repair capacityDNA interstrand cross-linksRepair capacityInterstrand cross-linksDisplacement of fluorideDNA repairCross-linkingAberrant DNA repairLesionsHealthy tissueBrain cancerRing openingHealthy cellsMGMTSelective chemotherapyGenotoxic agentsTumorChemical DNA modificationsCancerMultistep processRepair
2023
The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer
Al Assaad M, Gundem G, Liechty B, Sboner A, Medina J, Papaemmanuil E, Sternberg C, Marks A, Souweidane M, Greenfield J, Tran I, Snuderl M, Elemento O, Imielinski M, Pisapia D, Mosquera J. The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer. Molecular Case Studies 2023, 9: a006275. PMID: 37652664, PMCID: PMC10815291, DOI: 10.1101/mcs.a006275.Peer-Reviewed Original ResearchConceptsPediatric brain cancerPilocytic astrocytomaTargeted next-generation sequencingCase of pilocytic astrocytomaTumor size reductionLow-grade neoplasmsBrain cancerPediatric brain tumorsInternal tandem duplicationImpact treatment decisionsWhole-genome sequencingMolecular diagnosticsRNA-seq analysisRAS pathway activationNext-generation sequencingThalamic tumorsStable diseaseSuprasellar tumorsDabrafenib treatmentMultiple resectionsImprove patient outcomesTumor progressionWhole genomeRNA-seqTumorCCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastoma
Geraldo L, Garcia C, Xu Y, Leser F, Grimaldi I, de Camargo Magalhães E, Dejaegher J, Solie L, Pereira C, Correia A, De Vleeschouwer S, Tavitian B, Canedo N, Mathivet T, Thomas J, Eichmann A, Lima F. CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastoma. Cellular And Molecular Life Sciences 2023, 80: 179. PMID: 37314567, PMCID: PMC10267017, DOI: 10.1007/s00018-023-04788-7.Peer-Reviewed Original ResearchConceptsMicroglia/macrophage recruitmentC chemokine receptor type 7CCL21-CCR7Central nervous systemMacrophage recruitmentTumor microenvironmentChemokine receptor type 7Fatal primary tumorMouse GBM modelsChemokine ligand 21Potential therapeutic targetVEGF-A productionTumor cell deathCCR7 expressionTherapeutic optionsPrimary tumorPoor survivalCurrent treatmentGBM patientsTumor cell migrationTherapeutic targetBrain cancerNervous systemChemotherapy resistanceLigand 21
2022
Proxy ratings of psychological well‐being in patients with primary brain tumors: A systematic review
Sannes T, Yusufov M, Amonoo H, Broden E, Burgers D, Bain P, Pozo‐Kaderman C, Miran D, Smith T, Braun I, Pirl W. Proxy ratings of psychological well‐being in patients with primary brain tumors: A systematic review. Psycho-Oncology 2022, 32: 203-213. PMID: 36371618, PMCID: PMC10373343, DOI: 10.1002/pon.6063.Peer-Reviewed Original ResearchConceptsRates of depressionProxy ratingsJoanna Briggs Institute Critical Appraisal ChecklistSystematic reviewBrain cancer ratesCritical Appraisal ChecklistPotential risk of biasRisk of biasRatings of psychological well-beingNeuro-oncology patientsPsychological well-beingPatients' mood symptomsAppraisal checklistMethodological qualityDepression ratesWell-beingAnxietyDepressionMood symptomsRatersModerate levelsSample sizeBrain cancerPatientsJoannaMODL-22. Establishment of a novel system to specifically trace and ablate quiescent/slow cycling cells in high-grade glioma
Antonica F, Santomaso L, Pernici D, Petrucci L, Aiello G, Cutarelli A, Conti L, Romanel A, Miele E, Tebaldi T, Tiberi L. MODL-22. Establishment of a novel system to specifically trace and ablate quiescent/slow cycling cells in high-grade glioma. Neuro-Oncology 2022, 24: i173-i173. DOI: 10.1093/neuonc/noac079.645.Peer-Reviewed Original ResearchSlow-cycling cellsHigh-grade gliomasBrain cancerCancer organoidsTumor infiltrationHigh-grade brain cancerAdult high-grade gliomasTumor cellsHigh-grade glioma patientsCommon malignant brain tumorCycling tumor cellsPediatric high-grade glioma patientsMalignant brain tumorsSlow cycling stem cellsCycling cellsHuman tumor samplesPoor prognosisSurgical removalMalignant featuresTumor relapseGlioma patientsMouse modelBrain tumorsTemozolomide treatmentMalignant cells
2021
Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia–Chemotherapy Combination for Brain Cancer Treatment
Liu F, Wu H, Peng B, Zhang S, Ma J, Deng G, Zou P, Liu J, Chen AT, Li D, Bellone S, Santin AD, Moliterno J, Zhou J. Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia–Chemotherapy Combination for Brain Cancer Treatment. Nano Letters 2021, 21: 8111-8118. PMID: 34597054, DOI: 10.1021/acs.nanolett.1c02459.Peer-Reviewed Original ResearchConceptsBrain cancer treatmentSystemic chemotherapyCancer treatmentBrain cancer developmentNoninvasive deliverySystemic drug deliveryIntravenous administrationBrain tumorsIntracranial injectionBrain cancerTumor vasculatureCancer developmentImproved efficacyTumor cellsImproved treatmentMagnetic field exposureChemotherapyClinical applicationTumorsNoninvasive natureTreatmentDeliveryHyperthermiaField exposureCancer
2019
ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.Peer-Reviewed Original ResearchSerious adverse eventsAdverse eventsRecurrent glioblastomaOverall survivalOutcome measuresDevice-related serious adverse eventsMedian overall survivalProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureLong-term treatmentMulti-center studyAnti-cancer therapyProspective studyTreatment groupsFeasible treatmentPatientsBrain cancerInvestigator's choiceInvestigational deviceChemotherapyGlioblastomaMonthsTreatmentACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.Peer-Reviewed Original ResearchAdverse eventsOutcome measuresDevice-related serious adverse eventsSerious adverse eventsProgression-free survivalSecondary outcome measuresCessation of treatmentFurther prospective studiesPrimary outcome measureStandard of careMulti-center studyMild dysesthesiaSurgical debulkingOverall survivalProspective studyClinical utilityFeasible treatmentPatientsBrain cancerInvestigational deviceMonthsTreatmentGBMSurvivalDebulkingIn vivo 13C and 1H‐[13C] MRS studies of neuroenergetics and neurotransmitter cycling, applications to neurological and psychiatric disease and brain cancer
Rothman DL, de Graaf R, Hyder F, Mason GF, Behar KL, De Feyter HM. In vivo 13C and 1H‐[13C] MRS studies of neuroenergetics and neurotransmitter cycling, applications to neurological and psychiatric disease and brain cancer. NMR In Biomedicine 2019, 32: e4172. PMID: 31478594, DOI: 10.1002/nbm.4172.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2018
MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma
Zaman S, Chobrutskiy BI, Sikaria D, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma. Oncology Reports 2018, 41: 1359-1366. PMID: 30535461, DOI: 10.3892/or.2018.6896.Peer-Reviewed Original ResearchMAPT expressionSurvival rateΑ-synuclein gene expressionDisease-free survivalCentral nervous systemLow-grade gliomasAssociation of MAPTRate of survivalCancer Genome AtlasBreast cancerNeurodegenerative roleTau expressionBrain cancerNervous systemNeurological disordersTau proteinMAPT geneHigh expressionCancerGenome AtlasPrecursor proteinExpression levelsSuch associationsSurvivalTauACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.Peer-Reviewed Original ResearchDevice-related adverse eventsAdverse eventsOutcome measuresMaximal tumor debulkingSecond-line therapyProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureStandard of careMulti-center trialInvestigational medical deviceTreatment of glioblastomaClinical utility dataContinual therapyConcurrent therapyOverall survivalProspective studySafety profileTumor debulkingInterim safetyClinical utilityFeasible treatmentPatientsBrain cancerPassive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Kumar N, Pizzo M, Nehra G, Wilken-Resman B, Boroumand S, Thorne R. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjugate Chemistry 2018, 29: 3937-3966. PMID: 30265523, PMCID: PMC7234797, DOI: 10.1021/acs.bioconjchem.8b00548.Peer-Reviewed Original ResearchConceptsCentral nervous systemCNS disordersBlood-cerebrospinal fluid barrierTreatment of CNS disordersCentral nervous system disordersPotential treatment strategyTreating CNS disordersPassive immunotherapy approachesBlood-brain barrierImmunotherapy approachesNervous system disordersDrug deliveryPassive immunotherapyTreatment strategiesSystemic circulationFluid barrierTarget antigenSystem disordersDisease-specificNervous systemExogenous antibodiesBrain cancerAntibodiesTherapeutic antibody fragmentsDiseaseProspective memory impairment following whole brain radiotherapy in patients with metastatic brain cancer
Cheng H, Chen H, Lv Y, Chen Z, Li C. Prospective memory impairment following whole brain radiotherapy in patients with metastatic brain cancer. Cancer Medicine 2018, 7: 5315-5321. PMID: 30259694, PMCID: PMC6198199, DOI: 10.1002/cam4.1784.Peer-Reviewed Original ResearchConceptsDigit span testVerbal fluency testProspective memory impairmentMini-Mental State ExaminationTime-based prospective memory taskMemory impairmentProspective memory taskCognitive neuropsychological testsWhole brain radiotherapyMetastatic brain cancerMemory taskSpan testFluency testNeuropsychological testsBrain cancerState ExaminationBrain metastasesBrain radiotherapyCancer patientsImpairmentNonsignificant decreasePatientsTBPMRadiotherapyTaskImaging Dose, Cancer Risk and Cost Analysis in Image-guided Radiotherapy of Cancers
Zhou L, Bai S, Zhang Y, Ming X, Zhang Y, Deng J. Imaging Dose, Cancer Risk and Cost Analysis in Image-guided Radiotherapy of Cancers. Scientific Reports 2018, 8: 10076. PMID: 29973695, PMCID: PMC6031630, DOI: 10.1038/s41598-018-28431-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBone Marrow CellsBrainChildChild, PreschoolCone-Beam Computed TomographyCost-Benefit AnalysisFemaleHumansInfantLungMaleMiddle AgedMonte Carlo MethodNeoplasmsPhantoms, ImagingRadiation DosageRadiotherapy DosageRadiotherapy, Image-GuidedRisk FactorsThoraxYoung AdultConceptsCancer riskAssociated cancer riskImage-guided radiotherapyImaging proceduresLifetime attributable riskImaging dosesAverage lifetime attributable riskRadiological imaging proceduresRed bone marrowRetrospective studyCancer patientsLung cancerAttributable riskCancer incidenceBilling codesIndividual patientsBone marrowBrain cancerImage guidance proceduresPelvic scanPatientsCancerOrgan dosesRadiotherapyDoses
2017
Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme
Goods BA, Hernandez AL, Lowther DE, Lucca LE, Lerner BA, Gunel M, Raddassi K, Coric V, Hafler DA, Love JC. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. PLOS ONE 2017, 12: e0181538. PMID: 28880903, PMCID: PMC5589094, DOI: 10.1371/journal.pone.0181538.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-1 expressionEffector T cellsPD-1Effector cellsGlioblastoma multiformeCheckpoint inhibitorsTim-3T cellsHealthy subjectsCell death protein 1Features of exhaustionDeath protein 1T cell compartmentContext of GBMRecovery of functionCD4 effectorsCD4 cellsRNA sequencingTreatment of cancerHealthy donorsGBM patientsBrain cancerCD4Tumors
2016
Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging
Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano 2016, 10: 4209-4218. PMID: 26967254, PMCID: PMC5257033, DOI: 10.1021/acsnano.5b07573.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiological TransportBlood-Brain BarrierBrain NeoplasmsCell Line, TumorDecanoic AcidsDrug Delivery SystemsEthanolaminesFemaleGenetic TherapyHeterograftsHumansMatrix Metalloproteinase 2MiceMice, Inbred C57BLNanoparticlesOptical ImagingPaclitaxelPermeabilityPolymersPurinesPyrazolesScorpion VenomsTranscytosisTumor MicroenvironmentConceptsBlood-brain barrierLow delivery efficiencyTransport of nanoparticlesCancer gene therapyNanoparticle deliveryMore nanoparticlesBrain tumorsNanoparticlesDelivery efficiencyGene therapySystemic deliveryNPsBrain malignanciesBBB modulatorsPharmacological agentsBrain cancerBrain regionsTumorsDeliveryBrainImproved treatmentInadequate amountsPositive feedback loopChemotherapyMalignancyShort-Term Differentiation of Glioblastoma Stem Cells Induces Hypoxia Tolerance
Skjellegrind H, Fayzullin A, Johnsen E, Eide L, Langmoen I, Moe M, Vik-Mo E. Short-Term Differentiation of Glioblastoma Stem Cells Induces Hypoxia Tolerance. Neurochemical Research 2016, 41: 1545-1558. PMID: 26915110, PMCID: PMC4893075, DOI: 10.1007/s11064-016-1868-2.Peer-Reviewed Original ResearchConceptsGlioblastoma stem cellsAcute hypoxiaStem cellsShort-term differentiationHigh-grade malignancyCell calcium homeostasisMonitoring intracellular calciumWeeks of differentiationGlioblastoma treatment strategiesMalignant brain cancerDifferentiation of glioblastoma stem cellsMedian survivalIntracellular calciumSurgical removalTreatment resistancePatient biopsiesCalcium overloadTreatment strategiesMitochondrial membrane potentialCalcium homeostasisBasal metabolic rateMembrane potentialHypoxiaBrain cancerGlioblastoma
2015
The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium
Amirian ES, Armstrong GN, Zhou R, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Lachance D, Olson SH, Bernstein JL, Merrell RT, Wrensch MR, Davis FG, Lai R, Shete S, Amos CI, Scheurer ME, Aldape K, Alafuzoff I, Brännström T, Broholm H, Collins P, Giannini C, Rosenblum M, Tihan T, Melin BS, Bondy ML. The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. American Journal Of Epidemiology 2015, 183: 85-91. PMID: 26656478, PMCID: PMC4706682, DOI: 10.1093/aje/kwv235.Peer-Reviewed Original ResearchConceptsInternational case-control studyCase-control studyGlioma studiesGlioma International Case-Control StudyFatal brain cancerGenetic epidemiologyEtiological factorsBlood samplesGene-environment interactionsRetrospective exposure assessmentTumor subtypesBrain cancerMultiple data collection sitesSmall sample sizeBiospecimen collectionExposure assessmentInternational ConsortiumEpidemiologyCommon protocolSample sizeData collection sitesErratum: Hypoxia-cultured human adipose-derived mesenchymal stem cells are non-oncogenic and have enhanced viability, motility, and tropism to brain cancer
Feng Y, Zhu M, Dangelmajer S, Lee Y, Wijesekera O, Castellanos C, Denduluri A, Chaichana K, Li Q, Zhang H, Levchenko A, Guerrero-Cazares H, Quiñones-Hinojosa A. Erratum: Hypoxia-cultured human adipose-derived mesenchymal stem cells are non-oncogenic and have enhanced viability, motility, and tropism to brain cancer. Cell Death & Disease 2015, 6: e1797-e1797. PMID: 26111059, PMCID: PMC4669846, DOI: 10.1038/cddis.2015.176.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply